Day One
7:20 am Coffee & Registration
8:20 am Chair’s Opening Remarks
Harnessing the Power of PDXs to Accelerate Drug Development
8:30 am Preclinical Development of DuoBody®-CD3xB7H4 – a Novel CD3 Bispecific Antibody for the Treatment of Solid Cancers
Synopsis
- Exploring the preclinical use of CD3xB7H4 in humanised mice
- Analysing bispecific antibody development to treat cancers
9:00 am Presented by XenoSTART
9:30 am Investigating PDX Models to Study Resistance Mechanism of Neuroendocrine Prostate Cancers
Synopsis
- Showcasing data gathered from testing molecules of different PDX models
- Elucidating the mechanisms of resistance of prostate cancer to therapeutics
10:00 am Speed Networking
Synopsis
Join our speed networking session tailored for preclinical and translational experts to connect with industry peers & facilitating rapid yet meaningful exchanges of insights and expertise
10:30 am Morning Break & Networking
11:00 am Presented by Certis Oncology
Utilising Mouse Models to Investigate Tumour Resistance, Microenvironment, & Immunotherapy Anti-Tumour Mechanisms
11:30 am Utilising Humanised Mouse Models to Enhance Cancer Vaccine Research
Synopsis
- Evaluating the therapeutic effects of human PDC cell-based cancer vaccines in human-tumour bearing mouse models
- Exploring tumour resistance and evolution in humanised mouse models
- Characterising the human tumour microenvironment
- Demonstrating in vivo therapeutic efficacy
12:00 pm Presented by Lide
12:30 pm Lunch & Networking
1:30 pm Presented by GenOway
2:00 pm Investigating Safety & Efficacy of IOMX-0675 a Cross-Specific Antibody Unleashing Tumor Microenvironment Repolarisation & Activation by Targeting LILRB1/2 in Innovative In Vitro, Ex Vivo & Humanised In Vivo Cancer Models
Synopsis
- Selection and characterisation of the best-in class candidate IOMX-0675 using in vitro primary immune cells assays and ex vivo whole blood systems
- Translating myeloid – T cell biology into pharmacodynamic activity in advanced myeloid engrafted humanised mouse models
2:30 pm Development & Application of Innovative Models for Immunotherapy: Common Issues & Solutions in Non-Clinical Evaluation
Synopsis
- Models for NK Cell-Based Immunotherapy: huHSC-NCG-hIL2 or huHSC-NCG-hIL15?
- Models for T Cell-Based Immunotherapy: huPBMC-NCG or huPBMC-NCG-MHCI/II-DKO?
- Resistance Models: PD-1 resistance and HER2 resistance models
3:00 pm Afternoon Break & Networking
3:30 pm Utilising Novel GEMMs to Study Anti-Tumour Mechanisms of Prokarium’s ZH9 Immunotherapy Platform
Synopsis
- Introducing Prokarium’s product and goals of the platform
- Evaluating the right models for more advanced diseases
- Exploring the use of GEMMs to study bladder cancer
4:00 pm Assessing Techniques to Improve the TME for Therapeutic Discovery & Development
Synopsis
- Highlighting the importance of designing tumour models that accurately represent the immune component to effectively evaluate immuno-oncology therapies
- Uncovering methods for TME remodelling to promote immune activation
- Implementing tumour models including CDX/PDX mice and 3D tissue model systems to assess combination therapies of cancer vaccines with checkpoint inhibitors
4:30 pm OMX-0407 a Spectrum Selective Kinase Inhibitor Shows Preclinical & Clinical Efficacy in Angiosarcoma
Synopsis
- Demonstrating striking anti-tumour efficacy in a rare indication PDX of an Angiosarcoma with a comprehensive mode of action analysis
- Translating research into the first clinical findings with one responder patient in a Ph1a study
5:00 pm Closing Remarks
5:10 pm Tumour Models Drinks Reception & Poster Session
Synopsis
Join our dedicated drinks reception and poster session to further connect and network with like-minded experts whilst obtaining competitive insights from innovative work submitted by your peers!